Nipah virus (NiV) is a zoonotic RNA virus belonging to the genus Henipavirus within the family Paramyxoviridae. First identified in Malaysia in 1998, it gained global attention due to outbreaks characterized by encephalitis and severe respiratory symptoms. The natural reservoir is primarily fruit bats (Pteropodidae), with transmission occurring through direct contact with infected animals/their bodily fluids, consumption of contaminated food (e.g., date palm sap), and close human-to-human contact.

Human infection with Nipah virus (NiV) manifests with diverse clinical presentations, ranging from asymptomatic infection and acute respiratory syndrome to fatal encephalitis, with a case fatality rate of 40%-75%. Currently, there are no approved antiviral drugs or licensed vaccines specifically targeting NiV. Consequently, early case identification, patient isolation, and interruption of transmission chains constitute critical measures for outbreak control .

To address the urgent need for rapid diagnosis of Nipah virus (NiV) infection, BGI Gibel has developed a Nipah Virus Nucleic Acid Detection Kit (PCR-Fluorescent Probe Method) based on its established nucleic acid technology platform. This kit enables highly specific amplification and detection of targeted genomic regions of the virus, featuring operational simplicity, high sensitivity, and short turnaround time. In 2020, it participated in the calibration of reference materials for emerging acute infectious disease virus nucleic acid detection (including NiV) organized by the National Institutes for Food and Drug Control of China. The kit provides stable and reliable support for clinical and public health laboratories, facilitating early screening and confirmation of NiV infection to secure critical time for epidemic containment.